Aridis Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Louise Chen started Aridis Pharmaceuticals with an Overweight rating and $25 price target. The analyst sees successful advancement of the company’s pipeline, which focuses on targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections, driving the stock higher.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.